[go: up one dir, main page]

CA2528595A1 - Preparation and application of anti-tumor bifunctional fusion proteins - Google Patents

Preparation and application of anti-tumor bifunctional fusion proteins Download PDF

Info

Publication number
CA2528595A1
CA2528595A1 CA002528595A CA2528595A CA2528595A1 CA 2528595 A1 CA2528595 A1 CA 2528595A1 CA 002528595 A CA002528595 A CA 002528595A CA 2528595 A CA2528595 A CA 2528595A CA 2528595 A1 CA2528595 A1 CA 2528595A1
Authority
CA
Canada
Prior art keywords
preparation
application
fusion proteins
bifunctional fusion
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002528595A
Other languages
French (fr)
Inventor
Jing Ma
Yajun Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomax Acquisition Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 200310119930 external-priority patent/CN1297567C/en
Priority claimed from US10/723,003 external-priority patent/US20040254108A1/en
Priority claimed from TW92133577A external-priority patent/TW200427698A/en
Application filed by Individual filed Critical Individual
Publication of CA2528595A1 publication Critical patent/CA2528595A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Provided herein is a chimeric protein, which chimeric protein comprises a Flt3 ligand, or a biologically active fragment thereof, and a proteinuous or peptidyl tumoricidal agent, and uses thereof, particularly in the treatment of malignancy.

Claims
CA002528595A 2003-06-13 2004-06-04 Preparation and application of anti-tumor bifunctional fusion proteins Abandoned CA2528595A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN03129290.9 2003-06-13
CN03129290 2003-06-13
CN 200310119930 CN1297567C (en) 2003-06-13 2003-11-25 Double functional fusion protein possessing antineoplastic functions, method for making same and use thereof
CN2003101199300 2003-11-25
US10/723,003 2003-11-26
US10/723,003 US20040254108A1 (en) 2003-06-13 2003-11-26 Preparation and application of anti-tumor bifunctional fusion proteins
TW092133577 2003-11-28
TW92133577A TW200427698A (en) 2003-06-13 2003-11-28 Preparation and application of anti-tumor bifunctional fusion proteins
PCT/US2004/017765 WO2005001048A2 (en) 2003-06-13 2004-06-04 Preparation and application of anti-tumor bifunctional fusion proteins

Publications (1)

Publication Number Publication Date
CA2528595A1 true CA2528595A1 (en) 2005-01-06

Family

ID=33556472

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002528595A Abandoned CA2528595A1 (en) 2003-06-13 2004-06-04 Preparation and application of anti-tumor bifunctional fusion proteins

Country Status (5)

Country Link
EP (1) EP1633398A4 (en)
JP (1) JP2007515946A (en)
AU (1) AU2004252465A1 (en)
CA (1) CA2528595A1 (en)
WO (1) WO2005001048A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049750A1 (en) * 2009-10-20 2011-04-28 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding protein
CN104558194B (en) * 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 A kind of anti-CD20-Flex bifunctional fusion proteins, preparation method and the usage
KR20210003810A (en) 2018-04-18 2021-01-12 유씨엘 비즈니스 리미티드 Methods for enhancing the inhibitory properties of TREG cells
EA202191650A1 (en) 2018-12-18 2021-10-22 Бёрингер Ингельхайм Ио Канада Инк. FLT3 AGONISTIC ANTIBODIES AND THEIR APPLICATIONS
JP7729778B2 (en) * 2019-03-28 2025-08-26 オリオニス バイオサイエンシズ，インコーポレイテッド Chimeric proteins and chimeric protein complexes directed against FMS-like tyrosine kinase 3 (FLT3)
EP3946409A4 (en) * 2019-03-28 2023-06-21 Orionis Biosciences, Inc. Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins
JP7295283B2 (en) * 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド FLT3L-FC fusion proteins and methods of use
GB202007842D0 (en) 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy
GB202013477D0 (en) 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors

Also Published As

Publication number Publication date
WO2005001048A3 (en) 2005-06-16
EP1633398A4 (en) 2007-02-28
EP1633398A2 (en) 2006-03-15
JP2007515946A (en) 2007-06-21
WO2005001048A2 (en) 2005-01-06
AU2004252465A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
WO2003074551A3 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
AU2001257620A1 (en) Supplemental heart pump methods and systems for supplementing blood through the heart
AU1516301A (en) Use of a milk protein hydrolysate in the treatment of diabetes
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
AU6058500A (en) Fusion protein and uses thereof
AU7354400A (en) Guidable intravascular blood pump and related methods
WO2002083921A8 (en) Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
MXPA03008739A (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours.
USD466002S1 (en) Flexible pouch
WO2004001009A3 (en) Apo-2 ligand/trail variants and uses thereof
CA2528595A1 (en) Preparation and application of anti-tumor bifunctional fusion proteins
USD466800S1 (en) Flexible pouch
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
WO2006060021A3 (en) Bifunctional fusion proteins containing the flt3 ligand
AU2001235595A1 (en) 4-heteroaryl-1,4-diazabicyclo(3.2.2)nonane, preparation and therapeutic use thereof
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
AU2002247402A1 (en) Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
WO2004069206A3 (en) Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
AU2002246870A1 (en) Immunotherapeutic methods for extracorporeal modulation of cd36 and its ligands
AU2002233457A1 (en) Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
AU2002364808A1 (en) Polynucleotide and protein involved in synaptogenesis, variants thereof, and their therapeutic and diagnostic uses
GB2395903B (en) Dickkopf 5 gene, protein and antibodies: a role in the treatment and diagnosis of insulin-resistant states
AU6774198A (en) Human rab protein, srab
AU2002252773A1 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379

Legal Events

Date Code Title Description
FZDE Dead